Cyprus and Israel Join Forces For Groundbreaking Gene Editing Project

by News Editor

March 31, 2025

The Molecular Genetics Thalassaemia Department at the Cyprus Institute of Neurology & Genetics (CING) has launched EDIT-4-IRON, an ambitious genome editing initiative aimed at transforming treatments for iron-related blood disorders.

Backed by a €200,000 grant under the “RESTART 2016–2020, Bilateral Collaborations” program from the Research and Innovation Foundation, this 36-month project strengthens scientific ties between Cyprus and Israel while reinforcing both nations’ positions as leaders in genetic and haematological research.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

A Pioneering Collaboration

Led by Dr. Carsten W. Lederer, Head of the MGTD and Associate Professor at CING, the Cypriot team includes haematologist Dr. Panayiota L. Papasavva and gene editing expert Dr. Petros Patsali. On the Israeli side, gene editing specialist Dr. Ayal Hendel, a professor at Bar-Ilan University (BIU), spearheads the project.

Both institutions bring extensive expertise to the table. CING, the national reference laboratory for rare anaemia research and diagnosis in Cyprus, has been at the forefront of gene therapy innovations. BIU, meanwhile, holds multiple patents in editing technology and is a national leader in advanced therapy medicinal product development for blood disorders.

Training The Next Generation

Beyond its scientific breakthroughs, EDIT-4-IRON will provide cutting-edge training opportunities. The project supports two PhD students—one in Cyprus (Azzam Mohamed Ahmed Abdelfattah) and one in Israel—alongside an MSc student in Israel, offering them hands-on experience in gene therapy technologies and international networking prospects.

A Revolutionary Approach To Iron Disorders

EDIT-4-IRON aims to revolutionise treatments for inherited and acquired iron-related haematological disorders (IHDs), such as transfusion-dependent β-thalassaemia, non-transfusion-dependent thalassaemia, hereditary haemochromatosis, and polycythaemia vera. These conditions, often marked by iron overload or ineffective erythropoiesis, currently rely on small-molecule therapies that require lifelong administration and come with significant side effects.

By leveraging CRISPR/Cas and base editing technologies, researchers aim to create gene knockouts that induce an iron-restrictive state, potentially offering a long-term therapeutic alternative for thousands of patients worldwide.

A Data-Driven Approach

The project will rigorously evaluate the safety and efficacy of these gene-editing strategies through ex vivo and in vivo testing, using primary patient samples from Cyprus, cell lines, and murine disease models. This approach ensures that any breakthroughs can be translated into real-world clinical applications.

Setting the Stage For Innovation

EDIT-4-IRON officially kicked off on May 26, 2025, with a meeting between the Cypriot and Israeli teams to define collaboration frameworks, project milestones, and deliverables. With its combination of groundbreaking science, international cooperation, and a commitment to patient-centric innovation, this project marks a significant step forward in the fight against iron-related blood disorders.

The Future Forbes Realty Global Properties

Bank of Cyprus Upgrade Signals Fresh Optimism For Greek And Cypriot Banks

by THEFUTURE.TEAM

June 26, 2026

Regional Banks Enter A More Favorable Cycle

Bank of Cyprus and Eurobank are well positioned to benefit from a renewed re-rating of Greek and Cypriot bank stocks, according to Cyprus-based investment firm Roemer Capital, which upgraded Bank of Cyprus to a buy rating and reaffirmed its positive view on Eurobank.

The firm cited easing geopolitical tensions, resilient economic growth in Greece and Cyprus, lower funding costs and Greece’s expected transition to developed-market status as the main factors supporting the sector.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Roemer Capital also lowered its cost of equity assumptions, updated its forecasts following first-quarter 2026 results and extended its valuation horizon to the end of 2027, raising target prices across its banking coverage.

Bank Of Cyprus Gets The Largest Upgrade

Bank of Cyprus received the biggest revision, with Roemer Capital upgrading the stock from hold to buy and setting a target price of €11.10, implying potential total upside of 27%.

The firm highlighted the bank’s strong capital generation, profitability and projected 100% dividend payout, describing it as the strongest capital-return story among the banks under coverage. Roemer Capital maintained its buy rating on Eurobank, assigning a target price of €4.90 and forecasting potential upside of 28%. The report said the bank is well placed to benefit from loan growth, improving operating performance and merger-and-acquisition synergies.

National Bank of Greece and Piraeus Bank also retained buy ratings, with expected returns ranging from 25% to 36%. Optima Bank was upgraded to buy, while Alpha Bank remained at hold on valuation grounds.

Why Growth Still Sets The Region Apart

According to Roemer Capital, Greek and Cypriot banks continue to benefit from stronger economic fundamentals than many western European peers. The report pointed to faster economic growth, healthier balance sheets, low levels of non-performing exposures, capital ratios approaching 20% and strong customer deposit bases.

Analysts expect performing loans across the sector to grow at a compound annual rate of 6% to 8% through 2028, supported by private investment, digitalisation, green manufacturing, supply-chain expansion and a gradual recovery in household lending.

The report also said the conclusion of lending under the EU Recovery and Resilience Facility is unlikely to materially affect credit growth, as banks have already shifted back towards traditional commercial lending. Roemer Capital expects Euribor to remain between 2.2% and 2.5%, a level it believes should support both lending activity and net interest margins.

Geopolitics, Valuation And Market Structure Support The Case

The report said improving geopolitical conditions have strengthened the investment outlook, noting that Brent crude prices have largely returned to pre-war levels while Greek government bond yields have stabilised at around 3.5%. Although geopolitical risks remain, Roemer Capital believes the likelihood of a major inflationary shock or significant pressure on bank profitability has eased.

Another important catalyst identified by the firm is Greece’s expected promotion to developed-market status by FTSE Russell, STOXX and MSCI over the coming months.

According to the report, the reclassification should improve liquidity and attract a broader base of international investors. Roemer Capital also said Euronext’s acquisition of the Athens Exchange is expected to strengthen market infrastructure and increase international visibility, particularly for Bank of Cyprus and Optima Bank.

The firm noted that Bank of Cyprus has already benefited from its Athens listing, with average daily trading value increasing from less than €400,000 before its September 2024 move to nearly €6 million afterwards.

Economic Momentum Remains A Core Tailwind

Roemer Capital said both Greece and Cyprus have moved beyond post-crisis recovery and are now supported by private-sector-led growth. For Cyprus, the report highlighted recent tax reform and efforts to simplify the legal and regulatory framework, while also noting that limited foreign banking competition continues to support domestic lenders.

Overall, Roemer Capital expects Greek and Cypriot banks to remain well-positioned for profitable loan growth over the coming years.

Breaking news